- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Meet our expert team
Working at the cutting edge of epigenetics.
It’s all in our name: Volition means to have determination and a purpose.
We have a team of over 100 dedicated staff, spanning a wide range of disciplines.
We are dedicated to advancing the science of epigenetics and we are united in our mission to save lives and improve outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Cameron Reynolds MBA
President & Group Chief Executive Officer
Terig Hughes
Group Chief Financial Officer
Gaetan Michel PhD
Chief Operating Officer
Nick Plummer
Group General Counsel
Louise Batchelor
Group Chief Marketing & Communications Officer
Dr Andrew Retter BSC, MBBS, MRCP, FRCPATH(HAEM), DICM
Chief Medical Officer
Jake Micallef PhD. MBA
Chief Scientific Officer
Tom Butera DVM
Chief Executive Officer, Volition Veterinary Diagnostics Development LLC
Gael Forterre MBA
Chief Commercial Officer
Jasmine Kway PhD
Chief Executive Officer, Singapore Volition
Rod Rootsaert LLB
Corporate Secretary
Timothy I. Still
Chairman
Cameron Reynolds MBA
President & Group Chief Executive Officer
Guy Innes ACA
Independent Director
Mickie Henshall
Independent Director
Dr. Phillip Barnes BSc, PhD, BMBCh
Independent Director
Kim Nguyen
Independent Director
Dr Alan Colman
Independent Director & Member of Scientific Advisory Board
Dr. Ethel Rubin PhD
Independent Director